Comparative efficacy and safety of four long-acting granulocyte colony-stimulating factors for primary prophylaxis in patients with breast cancer: a prospective observational cohort study in China
Zihan Guo, Jinwei Hu, Miao Mo, Mengmeng Wang, Shuohan Huang, Tongtong Liu, Jiyong Liu, Qiong Du · 2026
Read Comparative efficacy and safety of four long-acting granulocyte colony-stimulating factors for primary prophylaxis in patients with breast cancer: a prospective observational cohort study in China by Zihan Guo, Jinwei Hu, Miao Mo, Mengmeng Wang, Shuohan Huang, Tongtong Liu, Jiyong Liu, Qiong Du (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13427526.txt.
Description
Zihan Guo and colleagues compared four long-acting white-cell growth factors head to head in breast cancer chemotherapy in a 2026 prospective observational cohort study in Shanghai, China. Long-acting granulocyte colony-stimulating factors are standard protection against chemotherapy-induced neutropenia, yet comparative data among products were limited. Patients at high risk of fever with low counts received pegfilgrastim, mecapegfilgrastim, telpegfilgrastim, or efbemalenograstim alfa once per cycle by clinical choice.
The main outcome was severe grade 3 or 4 neutropenia across cycles and follow-up, with bone pain tracked as the signature side effect. Direct comparison helps Chinese oncology centers choose among domestically available long-acting options.
Catalog record
| CREATOR | Zihan Guo, Jinwei Hu, Miao Mo, Mengmeng Wang, Shuohan Huang, Tongtong Liu, Jiyong Liu, Qiong Du |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45074 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |